ImageProVision Technology is a leading Indian company in the physical testing space with an emphasis on Image Analytics. ImageProVision’s products and services cater to pharmaceutical, life sciences, biotechnology, medical, chemical, and defence segments.
In a very short period of time, ImageProVision has created a dominant position in microscopic image analysis and has developed some path-breaking solutions for optical, polarised, hot stage, scanning electron microscopy. Some popular products like microscopic particle analysers, particle classifiers, particulate matter counters, nanoparticle analysers, smart proofreading systems, etc are being used by major Indian pharma companies. ImageProVision has also developed high technology products powered by machine learning and artificial intelligence.
With more than 140 installations at 60 customer locations, ImageProVision is working with leading pharma companies. These products are used in R&D for new drug development and in manufacturing QA/QC during drug production. All products comply with regulatory requirements such as 21 CFR compliance.
ImageProVision has a strong team of technology and domain experts. Innovation, being the core theme of ImageProVision’s culture. ImageProVision has won prestigious awards like Indian Pharma Award, Startup Masterclass Award, NASSCOM Emerge-50 award etc.
We have very aggressive plans for the Indian market. We plan to double our revenue this financial year compared to last year. We are progressing well with our plans.
We are investing in sales and marketing to reach the maximum number of customers. We are increasing our sales team and also investing in marketing by sponsoring major events and reaching customers. We have also significantly increased our investment in R&D with a dedicated laboratory for sample inspection and demonstration. New products powered by machine learning and artificial intelligence are being developed at our R&D.
We have an aggressive growth plan for the next three years, by growing at least five times of current size. Major factors are:
We are strengthening our team to prepare for exponential growth. New state-of-the-art technology development would enable new frontiers for growth.
Tell us about your international presence. Any plans to expand your footprints overseas?
We have recently started working in the North American market. Initial results are encouraging. However, we need to put the sales and support network to address the requirements of our customers in the US. Similarly, we have initiated our efforts in the European market. We see a very good potential in both the markets.
We have recently started working in the North American market. Initial results are encouraging. However, we need to put the sales and support network to address the requirements of the customer in the US. Similarly, we have initiated our efforts in the European market. We see a very good potential in both the markets.
The pharma sector becoming more concerned about regulatory aspects gives us a lot of opportunities. Our products are conforming to all regulatory requirements. Particle characterisation is a fundamental requirement of all R&D. Our new patented technology has helped many customers to successfully get regulatory approvals. Our initial success encourages us for exponential opportunities.
CPhI/P-Mec India is a major pharma event. We look forward to getting more insights into the market, customer expectations and new trends in the pharma industry.
